TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32205125

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 89
Study: 32419540

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fractional CO2-assisted photodynamic therapy (FrCO2 + PDT)
Number of subjects: 21
Study: 32507160

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training at moderate intensity (11-15/20 on the Borg scale), 3 times a week for 8 weeks.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no exercise training).
Number of subjects: 28
Study: 616279764

Group type: EXPERIMENTAL
Intervention: Team-based competition (Regions Conference Cup)
Number of subjects: 13
Study: 35862038

Group type: EXPERIMENTAL
Intervention: Marine ω-3 fatty acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34719908

Group type: EXPERIMENTAL
Intervention: Electromyostimulation in motion during therapeutic gymnastics
Number of subjects: 51

Group type: COMPARATOR
Intervention: Therapeutic gymnastics recommended for lymphovenous insufficiency (Control)
Number of subjects: 51
Study: 32925788

Group type: EXPERIMENTAL
Intervention: Acupoint thread embedding treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Climen tablet (0.3 mg, 1 tablet/day)
Number of subjects: 70
Study: 36070301

Group type: EXPERIMENTAL
Intervention: oral alfacalcidol
Number of subjects: 976
Study: 34684348

Group type: EXPERIMENTAL
Intervention: Healthy Habits Plus (six telephone calls)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Time2bHealthy (six online modules)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Active control (ten information sheets and a summary booklet)
Number of subjects: 458
Study: 35201381

Group type: EXPERIMENTAL
Intervention: Anodal stimulation of the left posterior parietal cortex (2 mA for 20 min) followed by motor practice
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham stimulation followed by motor practice
Number of subjects: 28
Study: 34076288

Group type: EXPERIMENTAL
Intervention: Spironolactone therapy (Group PVI/SP)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control (Group PVI alone)
Number of subjects: 203
Study: 32176744

Group type: EXPERIMENTAL
Intervention: Esophageal cancer patients with ERF
Number of subjects: 46

Group type: COMPARATOR
Intervention: Esophageal cancer patients without ERF (Control)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vocal fold paralysis in ERF
Number of subjects: 46
Study: 36327532

Group type: EXPERIMENTAL
Intervention: Internet-based emotional awareness and expression therapy (I‐EAET) for 10 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 74
Study: 34530594

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice a day) plus Aspirin (100 mg once a day)
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Rivaroxaban (5 mg twice a day) alone
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Aspirin (100 mg once a day) alone
Number of subjects: 1086
Study: 35225542

Group type: EXPERIMENTAL
Intervention: Vitrectomy with multilayered inverted internal limiting membrane flap technique (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vitrectomy with standard ILM peeling (Group A)
Number of subjects: 150
Study: 32918907

Group type: EXPERIMENTAL
Intervention: Forced aerobic exercise and upper extremity repetitive task practice (FE+RTP) [n=16]
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Voluntary aerobic exercise and upper extremity repetitive task practice (VE+RTP) [n=14]
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-aerobic control group [n=13]
Number of subjects: 43
Study: 36404687

Group type: EXPERIMENTAL
Intervention: Combined agent flurbiprofen 8.75 mg and cetylpyridinium chloride 1.0 mg in the form of tablets for resorption
Number of subjects: 266

Group type: COMPARATOR
Intervention: Cetylpyridinium chloride 1.2 mg in the form of medicinal lozenges
Number of subjects: 266
Study: 33491594

Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (6.4 g·d-1) for 28 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo group (PLA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (BA and PLA)
Number of subjects: 19
Study: 32250301

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal sleep control
Number of subjects: 11
Study: 36014880

Group type: EXPERIMENTAL
Intervention: Water-soluble tomato concentrate (WSTC)
Number of subjects: 52
Study: 34336888

Group type: EXPERIMENTAL
Intervention: 577‐nm subthreshold micropulse laser (SML)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 577‐nm conventional laser (CL)
Number of subjects: 110
Study: 34281854

Group type: EXPERIMENTAL
Intervention: Zoledronic Acid (ZA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RANKL inhibitors (RANKL-I)
Number of subjects: 0
Study: 33506810

Group type: EXPERIMENTAL
Intervention: Early low-molecular-weight heparin (LMWH) administration within 7 days from COVID-19 signs and symptoms onset
Number of subjects: 93

Group type: COMPARATOR
Intervention: Delayed low-molecular-weight heparin (LMWH) administration after 7 days
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Early low-molecular-weight heparin (LMWH) administration
Number of subjects: 93
Study: 33595663

Group type: EXPERIMENTAL
Intervention: Treated diastolic blood pressure less than 60 mm Hg
Number of subjects: 7515

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure between 70 and 80 mm Hg
Number of subjects: 7515
Study: 33811776

Group type: EXPERIMENTAL
Intervention: Adsorbent lotion containing tapioca starch, spent grain wax, Butyrospermum parkii extract, argania spinosa kernel oil, aloe barbadensis, rosehip oil, and allantoin applied twice daily.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adsorbent lotion
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% hydrocortisone cream applied twice daily.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adsorbent lotion and 1% hydrocortisone cream
Number of subjects: 40
Study: 34238698

Group type: EXPERIMENTAL
Intervention: Electrocauterization after removal of apocrine sweat glands
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided BOTOX injection
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Electrocauterization after removal of apocrine sweat glands followed by ultrasound-guided BOTOX injection after two weeks
Number of subjects: 90
Study: 32481441

Group type: COMPARATOR
Intervention: Sufentanil 1.78 µg/kg (group S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nalbuphine 1.78 mg/kg (group N)
Number of subjects: 60
Study: 36412288

Group type: EXPERIMENTAL
Intervention: Soccer injury prevention education group (intervention group)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 502
Study: 34911901

Group type: EXPERIMENTAL
Intervention: PVI‐plus (pulmonary vein isolation plus extensive ablation strategy)
Number of subjects: 497

Group type: COMPARATOR
Intervention: PVI‐alone (pulmonary vein isolation only)
Number of subjects: 497
Study: 32045638

Group type: EXPERIMENTAL
Intervention: HES50 (50 mg kg‐1 hesperidin)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: HES75 (75 mg kg‐1 hesperidin)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: HES100 (100 mg kg‐1 hesperidin)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: HES150 (150 mg kg‐1 hesperidin)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: HES50-150 (50-150 mg kg‐1 hesperidin)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control (basal diet)
Number of subjects: 900
Study: 32352832

Group type: EXPERIMENTAL
Intervention: Mindfulness-based training (MBT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Adaptive cognitive training (aCT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist (WL) control
Number of subjects: 61
Study: 36214729

Group type: EXPERIMENTAL
Intervention: Enzyme-containing mouthwash
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 35
Study: 34433653

Group type: EXPERIMENTAL
Intervention: Spartalizumab (400 mg once every 4 weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Chemotherapy (per investigator's choice)
Number of subjects: 122
Study: 32105221

Group type: EXPERIMENTAL
Intervention: 5% HF for 30 seconds (HF5-30)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 5% HF for 60 seconds (HF5-60)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 5% HF for 90 seconds (HF5-90)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 10% HF for 30 seconds (HF10-30)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 10% HF for 60 seconds (HF10-60)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 10% HF for 90 seconds (HF10-90)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 91
Study: 631198356

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering treatment
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard blood pressure lowering treatment
Number of subjects: 1000
Study: 35277055

Group type: EXPERIMENTAL
Intervention: Early introduction of standardized complementary food (10–12 weeks of life)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Late introduction of standardized complementary food (16–18 weeks of life)
Number of subjects: 177
Study: 34195767

Group type: EXPERIMENTAL
Intervention: Pectoral nerve block
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no pectoral nerve block)
Number of subjects: 73
Study: 32052249

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35998002

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) during IV blood draw
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard practice during IV blood draw
Number of subjects: 59
Study: 34329196

Group type: EXPERIMENTAL
Intervention: >0-0.5 servings/week
Number of subjects: 91891

Group type: EXPERIMENTAL
Intervention: >0.5-1 serving/week
Number of subjects: 91891

Group type: EXPERIMENTAL
Intervention: >1-2 servings/week
Number of subjects: 91891

Group type: EXPERIMENTAL
Intervention: >2 servings/week
Number of subjects: 91891

Group type: COMPARATOR
Intervention: Chocolate consumption
Number of subjects: 91891
Study: 32917369

Group type: EXPERIMENTAL
Intervention: PM2.5 exposure
Number of subjects: 5028

Group type: EXPERIMENTAL
Intervention: PM10 exposure
Number of subjects: 5028

Group type: EXPERIMENTAL
Intervention: SO2 exposure
Number of subjects: 5028

Group type: EXPERIMENTAL
Intervention: O3 exposure
Number of subjects: 5028
Study: 35077474

Group type: EXPERIMENTAL
Intervention: rasagiline (1 mg/day)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: rasagiline (0.5 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: rasagiline (monotherapy)
Number of subjects: 2
Study: 34337284

Group type: EXPERIMENTAL
Intervention: ATTUNE knee implant system
Number of subjects: 150

Group type: COMPARATOR
Intervention: P.F.C. SIGMA knee implant system
Number of subjects: 150
Study: 34987324

Group type: EXPERIMENTAL
Intervention: Dry needling with conventional therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neural mobilization with conventional therapy
Number of subjects: 36
Study: 34011163

Group type: EXPERIMENTAL
Intervention: CABG with complete revascularization (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG with incomplete revascularization (IR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCI with complete revascularization (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCI with incomplete revascularization (IR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCI with rSS=0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCI with rSS>0-4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCI with rSS>4-8
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCI with rSS>8
Number of subjects: 0
Study: 32966163

Group type: EXPERIMENTAL
Intervention: Self-efficacy scales related to speech, social, emotional, and cognitive components of stuttering.
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Self-reported success in treatment, beliefs about the importance of multidimensional treatment, and self-reported empathy.
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Academic and clinical training in fluency disorders.
Number of subjects: 320
Study: 35875033

Group type: EXPERIMENTAL
Intervention: Special day for men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deployment of male champions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incentive (food package) for couples
Number of subjects: 0
Study: 33229928

Group type: EXPERIMENTAL
Intervention: Apolipoprotein B measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional lipid markers (total cholesterol, triglycerides, LDL-cholesterol, non-HDL-cholesterol)
Number of subjects: 0
Study: 35239707

Group type: EXPERIMENTAL
Intervention: Tea making training (5 sessions of 1 hour each)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Stepping training (5 sessions of 1 hour each)
Number of subjects: 25
Study: 33277162

Group type: EXPERIMENTAL
Intervention: Pre-operative carbohydrate drinks
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard care (fasting from midnight with free clear fluids until two hours prior to surgery)
Number of subjects: 184
Study: 35932067

Group type: EXPERIMENTAL
Intervention: Transport PLUS intervention (administered by trained EMTs)
Number of subjects: 439
Study: 35931131

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension (USLS)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Increase of 5 kg/m2 in BMI
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Increase of 1 year in duration of prolapse symptoms
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Women with >5 years of prolapse symptoms
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Women who are obese and overweight
Number of subjects: 173
Study: 32610266

Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral DCB
Number of subjects: 1980

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral DCB (broader use)
Number of subjects: 1980
Study: 34791269

Group type: EXPERIMENTAL
Intervention: Concomitant cryoablation during mitral valve surgery
Number of subjects: 242
Study: 32777032

Group type: EXPERIMENTAL
Intervention: Highest quartile of clinicians' antibiotic prescribing rate (80.2%)
Number of subjects: 232256

Group type: COMPARATOR
Intervention: Lowest quartile of clinicians' antibiotic prescribing rate (42.1%)
Number of subjects: 232256

Group type: EXPERIMENTAL
Intervention: Patients seen by the highest-prescribing clinicians
Number of subjects: 232256
Study: 35263558

Group type: EXPERIMENTAL
Intervention: Antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo contact lens (etafilcon A with no added drug)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Both test and placebo lenses
Number of subjects: 560
Study: 34396402

Group type: EXPERIMENTAL
Intervention: Technology Enhanced Community Health Precision Nursing (TECH-PN) intervention with unlimited precision care services driven by interim STI and macrolide resistance testing results.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group receiving 1 community nursing visit with self-management for interim care per national guidelines.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Baseline laboratory results for STI assessment.
Number of subjects: 76
Study: 32730798

Group type: EXPERIMENTAL
Intervention: Osilodrostat (1–30 mg twice daily)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Osilodrostat
Number of subjects: 137
Study: 35789381

Group type: EXPERIMENTAL
Intervention: SER-109 (investigational oral microbiome therapeutic)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Cdiff32 questionnaire
Number of subjects: 182
Study: 34293010

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA)
Number of subjects: 1405

Group type: COMPARATOR
Intervention: Control group (no BTA)
Number of subjects: 1405
Study: 35379626

Group type: EXPERIMENTAL
Intervention: SUCCESS stop smoking strategy delivered by trained practice assistants after cervical smear
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SUCCESS stop smoking strategy
Number of subjects: 0
Study: 34749808

Group type: EXPERIMENTAL
Intervention: Calcium polyP microparticles (Ca‐polyP MPs) only
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of Calcium polyP microparticles (Ca‐polyP MPs) and biphasic calcium phosphate (BCP)
Number of subjects: 8
Study: 35109953

Group type: EXPERIMENTAL
Intervention: Multivitamin, mineral and n-3 polyunsaturated fatty acid supplementation
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 34171709

Group type: EXPERIMENTAL
Intervention: PresStim group (Dynamic RTPS and NS set at 1.5 mA then decreased; n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (fixed thresholds for in‐line pressure mechanical manometer and NS at 0.2 mA; n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 35258510

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: GEM/nab-PTX
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 51
Study: 32493434

Group type: EXPERIMENTAL
Intervention: Community-based interactive youth educational program alone (Group A)
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Community-based interactive youth educational program followed by an Internet-based booster (Group B)
Number of subjects: 1979

Group type: COMPARATOR
Intervention: No-interaction control (Group C)
Number of subjects: 1979
Study: 36275772

Group type: EXPERIMENTAL
Intervention: 50 µg bivalent NoV vaccine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 150 µg bivalent NoV vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both dose levels of the vaccine
Number of subjects: 60
Study: 34224213

Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 1659
Study: 35559854

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol use and coping
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol use only
Number of subjects: 499

Group type: COMPARATOR
Intervention: Control topics
Number of subjects: 499
Study: 32902905

Group type: EXPERIMENTAL
Intervention: Five SMS per week
Number of subjects: 3994

Group type: EXPERIMENTAL
Intervention: Three SMS per week
Number of subjects: 3994

Group type: COMPARATOR
Intervention: Zero SMS per week
Number of subjects: 3994

Group type: EXPERIMENTAL
Intervention: Face-to-face consultation with a diabetes educator
Number of subjects: 3994

Group type: EXPERIMENTAL
Intervention: Call from a dietitian
Number of subjects: 3994

Group type: EXPERIMENTAL
Intervention: Enrolled with pharmacists
Number of subjects: 3994
Study: 35875694

Group type: EXPERIMENTAL
Intervention: 1200 IU (30 µg) capsules of vitamin D3 once per day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo oil capsules once per day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 53
Study: 32412388

Group type: EXPERIMENTAL
Intervention: Working Alliance Inventory short-form (WAI-S)
Number of subjects: 338
Study: 32130806

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir plus rilpivirine
Number of subjects: 566

Group type: COMPARATOR
Intervention: Oral therapy with dolutegravir-abacavir-lamivudine
Number of subjects: 566
Study: 34941354

Group type: EXPERIMENTAL
Intervention: CAPS‐5 (Clinician‐Administered PTSD Scale for DSM‐5)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: PCL‐5 (PTSD Checklist for DSM‐5)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Reliable or clinically significant change (CSC)
Number of subjects: 198
Study: 32264972

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 35379189

Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade combined with transverse abdominal plane block (M group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Deep neuromuscular blockade (D group)
Number of subjects: 80
Study: 34352845

Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation)
Number of subjects: 109

Group type: COMPARATOR
Intervention: IV sedation (fentanyl, midazolam)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Physician perception of pain in TENS group
Number of subjects: 109

Group type: COMPARATOR
Intervention: Physician perception of pain in IV group
Number of subjects: 109
Study: 35764205

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (≥1,000 IU/day for ≥4 days/week)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (did not use vitamin D in the past 30 days)
Number of subjects: 236
Study: 33301475

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 106

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 106
Study: 33081083

Group type: EXPERIMENTAL
Intervention: Rose extract treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epinephrine (induced skin stress response)
Number of subjects: 0
Study: 37382230

Group type: EXPERIMENTAL
Intervention: Proficiency-based progression (PBP) training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional training (TT)
Number of subjects: 36
Study: 36257349

Group type: EXPERIMENTAL
Intervention: Mixed lipid emulsion containing fish oil
Number of subjects: 206

Group type: COMPARATOR
Intervention: Soybean oil-based lipid emulsion
Number of subjects: 206
Study: 33616606

Group type: EXPERIMENTAL
Intervention: Cancer drugs with positive reimbursement recommendation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cancer drugs with negative reimbursement recommendation
Number of subjects: 104